MedTrace Logo

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

NCT07340138 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-04-29

No results posted yet for this study

Summary

This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).

Conditions

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera Myelofibrosis (Post-PV MF)
  • Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

DRUG

Pelabresib

125 mg orally once daily (QD) on Days 1-14 of each 21-day cycle

DRUG

Ruxolitinib

5-25 mg twice daily (BID)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2026-11-16
Completion
2030-12-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07340138 on ClinicalTrials.gov